Max J Rieger, Andreas J Flammer, Sabine Gerull, Thomas Pabst, Holger W Auner, Kaveh Samii, Felicitas Hitz, Ulrich Mey, Veronika Ballova, Raphael Battegay, Giorgia Melli, Dominik Benz, Yakup Yakupoglu, Christoph Gräni, Regina Schläger, Sarah Hugelshofer, Annina Studer, Luca Oechslin, Adam Bakula, Thomas M Suter, Julia Leo-Stickelberger, Manuela Averiamo, Thomas Fehr, Hans H Jung, Natallia Laptseva, Robert Manka, Axel Rüfer, Adrian Schmidt, Harald Seeger, Beat Müllhaupt, Simon F Stämpfli, Carmen De Ramon Ortiz, Marie Théaudin, Bernhard Gerber, Rahel Schwotzer
{"title":"瑞士淀粉样变性网络对轻链淀粉样变性治疗的最新建议。","authors":"Max J Rieger, Andreas J Flammer, Sabine Gerull, Thomas Pabst, Holger W Auner, Kaveh Samii, Felicitas Hitz, Ulrich Mey, Veronika Ballova, Raphael Battegay, Giorgia Melli, Dominik Benz, Yakup Yakupoglu, Christoph Gräni, Regina Schläger, Sarah Hugelshofer, Annina Studer, Luca Oechslin, Adam Bakula, Thomas M Suter, Julia Leo-Stickelberger, Manuela Averiamo, Thomas Fehr, Hans H Jung, Natallia Laptseva, Robert Manka, Axel Rüfer, Adrian Schmidt, Harald Seeger, Beat Müllhaupt, Simon F Stämpfli, Carmen De Ramon Ortiz, Marie Théaudin, Bernhard Gerber, Rahel Schwotzer","doi":"10.57187/s.4219","DOIUrl":null,"url":null,"abstract":"<p><p>Since the publication of the first Swiss recommendations on systemic light-chain amyloidosis in 2020, treatment strategies have evolved. As a result of the third joint meeting of the Swiss Amyloidosis Network, a multidisciplinary and multicentre Swiss clinical consortium, in 2024, recommendations for the treatment of light-chain amyloidosis were updated. They discuss the role of the new standard first-line protocol Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone (Dara-CyBorD), the timing and indication of high-dose treatment and potential second-line strategies as well as emerging treatment options, with a special focus on multidisciplinary supportive care measures. The update represents a synopsis of current evidence and expert consensus and intends to provide general treatment guidance tailored to the Swiss healthcare system. Nonetheless, treatment decisions should always be personalised and involve a multidisciplinary approach. This update replaces the previous \"therapeutic recommendations\" while the previous \"diagnostic recommendations\" remain valid.</p>","PeriodicalId":22111,"journal":{"name":"Swiss medical weekly","volume":"155 ","pages":"4219"},"PeriodicalIF":1.9000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Updated recommendations for the treatment of light-chain amyloidosis from the Swiss Amyloidosis Network.\",\"authors\":\"Max J Rieger, Andreas J Flammer, Sabine Gerull, Thomas Pabst, Holger W Auner, Kaveh Samii, Felicitas Hitz, Ulrich Mey, Veronika Ballova, Raphael Battegay, Giorgia Melli, Dominik Benz, Yakup Yakupoglu, Christoph Gräni, Regina Schläger, Sarah Hugelshofer, Annina Studer, Luca Oechslin, Adam Bakula, Thomas M Suter, Julia Leo-Stickelberger, Manuela Averiamo, Thomas Fehr, Hans H Jung, Natallia Laptseva, Robert Manka, Axel Rüfer, Adrian Schmidt, Harald Seeger, Beat Müllhaupt, Simon F Stämpfli, Carmen De Ramon Ortiz, Marie Théaudin, Bernhard Gerber, Rahel Schwotzer\",\"doi\":\"10.57187/s.4219\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Since the publication of the first Swiss recommendations on systemic light-chain amyloidosis in 2020, treatment strategies have evolved. As a result of the third joint meeting of the Swiss Amyloidosis Network, a multidisciplinary and multicentre Swiss clinical consortium, in 2024, recommendations for the treatment of light-chain amyloidosis were updated. They discuss the role of the new standard first-line protocol Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone (Dara-CyBorD), the timing and indication of high-dose treatment and potential second-line strategies as well as emerging treatment options, with a special focus on multidisciplinary supportive care measures. The update represents a synopsis of current evidence and expert consensus and intends to provide general treatment guidance tailored to the Swiss healthcare system. Nonetheless, treatment decisions should always be personalised and involve a multidisciplinary approach. This update replaces the previous \\\"therapeutic recommendations\\\" while the previous \\\"diagnostic recommendations\\\" remain valid.</p>\",\"PeriodicalId\":22111,\"journal\":{\"name\":\"Swiss medical weekly\",\"volume\":\"155 \",\"pages\":\"4219\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-07-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Swiss medical weekly\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.57187/s.4219\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Swiss medical weekly","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.57187/s.4219","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Updated recommendations for the treatment of light-chain amyloidosis from the Swiss Amyloidosis Network.
Since the publication of the first Swiss recommendations on systemic light-chain amyloidosis in 2020, treatment strategies have evolved. As a result of the third joint meeting of the Swiss Amyloidosis Network, a multidisciplinary and multicentre Swiss clinical consortium, in 2024, recommendations for the treatment of light-chain amyloidosis were updated. They discuss the role of the new standard first-line protocol Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone (Dara-CyBorD), the timing and indication of high-dose treatment and potential second-line strategies as well as emerging treatment options, with a special focus on multidisciplinary supportive care measures. The update represents a synopsis of current evidence and expert consensus and intends to provide general treatment guidance tailored to the Swiss healthcare system. Nonetheless, treatment decisions should always be personalised and involve a multidisciplinary approach. This update replaces the previous "therapeutic recommendations" while the previous "diagnostic recommendations" remain valid.
期刊介绍：
The Swiss Medical Weekly accepts for consideration original and review articles from all fields of medicine. The quality of SMW publications is guaranteed by a consistent policy of rigorous single-blind peer review. All editorial decisions are made by research-active academics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
